Peter A Kaufman

11PUBLICATIONS
105CO-AUTHORS
Models of care and place of birthCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHealth and ecological risk assessmentMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 29, 2026
Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer.

Gregory A Vidal, Julie Katz, Natalia Sadetsky

|Dec 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.

Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton

|Oct 08, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

Patrick Neven, Nicole Stahl, Maria Vidal

|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn

|Feb 04, 2024
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.

Ravi K Goyal, Jingchuan Zhang, Keith L Davis

|Oct 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Matthew P Goetz, Erika P Hamilton, Mario Campone

Pageof 2

Frequent Collaborators

4 joint publications

Erika P Hamilton

3 joint publications

Miguel Martin

3 joint publications

Seock-Ah Im

3 joint publications

Bastien Nguyen